AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19058232 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylate (5-ASA)
Number of subjects: 1048
Study 19058232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1048
Study 17217450 — intervention group
Group type: EXPERIMENTAL
Intervention: NK-1 receptor antagonist (NK-1RA)
Number of subjects: 14
Study 17217450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15896583 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hemodilution group (group A, N=15) with hematocrit level of 32%
Number of subjects: 30
Study 15896583 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hemodilution group (group B, N=15) with hematocrit level of 24%
Number of subjects: 30
Study 12135828 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin intake regulation methods based on experience-based knowledge
Number of subjects: 10
Study 12135828 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative insights from semi-structured interviews
Number of subjects: 10
Study 9884136 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverages (1 ml alcohol)
Number of subjects: 20
Study 9884136 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 g/kg of alcohol beverages
Number of subjects: 20
Study 7481209 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 1229
Study 7481209 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant systemic therapy (control)
Number of subjects: 1229
Study 2650582 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (20-80 mg/day)
Number of subjects: 172
Study 2650582 — intervention group
Group type: COMPARATOR
Intervention: Captopril (50-200 mg/day)
Number of subjects: 172
Study 352484 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.15 mg/kg intramuscularly for premedication and 0.3 mg/sec intravenously for induction)
Number of subjects: 40
Study 352484 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (as an induction agent)
Number of subjects: 40
Study 352484 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (premedication and induction)
Number of subjects: 40
Study 352484 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (premedication)
Number of subjects: 40
Study 352484 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (1 mg/kg)
Number of subjects: 40
Study 352484 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (2.5 mg/sec)
Number of subjects: 40
Study 30368628 — intervention group
Group type: EXPERIMENTAL
Intervention: An Individualized Mental Health Intervention for Children with ASD (AIM HI)
Number of subjects: 0
Study 30368628 — intervention group
Group type: COMPARATOR
Intervention: AIM HI
Number of subjects: 0
Study 28503725 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-extraction treatment with fixed appliances for a mean period of 2.46 years
Number of subjects: 60
Study 28503725 — intervention group
Group type: COMPARATOR
Intervention: Extraction treatment with fixed appliances for a mean period of 2.49 years
Number of subjects: 60
Study 26404337 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved water supply in intervention communities
Number of subjects: 607
Study 26404337 — intervention group
Group type: COMPARATOR
Intervention: Control communities with no intervention
Number of subjects: 607
Study 24777970 — intervention group
Group type: COMPARATOR
Intervention: OLP alone
Number of subjects: 12
Study 24777970 — intervention group
Group type: EXPERIMENTAL
Intervention: OLP in Montanide
Number of subjects: 12
Study 24777970 — intervention group
Group type: EXPERIMENTAL
Intervention: OLP and poly-ICLC in Montanide
Number of subjects: 12
Study 21321613 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rinse of Turkish gall
Number of subjects: 70
Study 21321613 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral hygiene only (Control)
Number of subjects: 70
Study 18727139 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session educational intervention
Number of subjects: 30
Study 18727139 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 17485971 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + Valsartan combination therapy
Number of subjects: 0
Study 17485971 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (2.5 or 5 mg/d; 10 mg/d)
Number of subjects: 0
Study 17485971 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (40, 80, 160, or 320 mg/d)
Number of subjects: 0
Study 17485971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15460635 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic gas mixture (F(IO)2 = 12.2%, equivalent to 4000 m)
Number of subjects: 16
Study 15460635 — intervention group
Group type: COMPARATOR
Intervention: Normoxic room air (F(IO)2 = 20.9%)
Number of subjects: 16
Study 15460635 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic gas mixture (F(IO)2 = 12.2%)
Number of subjects: 16
Study 11437015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg daily for 2 weeks, then increased to 20 mg daily, with possible increase to 60 mg daily)
Number of subjects: 103
Study 11437015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 10220010 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 46
Study 10220010 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy subjects)
Number of subjects: 46
Study 7541003 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 52
Study 7541003 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG laser therapy
Number of subjects: 52
Study 2150533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure recordings
Number of subjects: 2000
Study 2150533 — intervention group
Group type: COMPARATOR
Intervention: Office blood pressure recordings
Number of subjects: 2000
Study 2150533 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated hypertensives with randomly allocated treatment
Number of subjects: 2000
Study 480560 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridology
Number of subjects: 143
Study 480560 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 143
Study 31691002 — intervention group
Group type: COMPARATOR
Intervention: Lower socioeconomic position (SEP)
Number of subjects: 4787
Study 31691002 — intervention group
Group type: COMPARATOR
Intervention: Current smoking and low fruit consumption
Number of subjects: 4787
Study 31691002 — intervention group
Group type: COMPARATOR
Intervention: Potential mediating risk factors (body mass index, diabetes, smoking, dietary factors)
Number of subjects: 4787
Study 28165768 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BTJ)
Number of subjects: 34
Study 28165768 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo (PLA)
Number of subjects: 34
Study 25848938 — intervention group
Group type: COMPARATOR
Intervention: Area-level Index of Multiple Deprivation (IMD) 2007
Number of subjects: 50029
Study 25848938 — intervention group
Group type: COMPARATOR
Intervention: Education level
Number of subjects: 50029
Study 23422374 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone starting dose of 3 mg/d; subsequent dosing range of 3 to 6 mg/d for adolescents less than 51 kg and 3 to 12 mg/d for adolescents greater than or equal to 51 kg.
Number of subjects: 0
Study 23422374 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone
Number of subjects: 0
Study 21552707 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan mouthrinse
Number of subjects: 50
Study 21552707 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse
Number of subjects: 50
Study 21552707 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatic solution
Number of subjects: 50
Study 21552707 — intervention group
Group type: COMPARATOR
Intervention: Cetilpiridine chloride associated with sodium chloride mouthrinse
Number of subjects: 50
Study 21552707 — intervention group
Group type: COMPARATOR
Intervention: Distilled water mouthrinse
Number of subjects: 50
Study 19856793 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxsuprine hydrochloride 30 mg
Number of subjects: 0
Study 19856793 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxsuprine hydrochloride 60 mg
Number of subjects: 0
Study 19856793 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxsuprine hydrochloride 90 mg
Number of subjects: 0
Study 19856793 — intervention group
Group type: COMPARATOR
Intervention: Isoxsuprine hydrochloride 10 mg (i.m. route)
Number of subjects: 0
Study 19856793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and i.m. routes
Number of subjects: 0
Study 19856793 — intervention group
Group type: EXPERIMENTAL
Intervention: All four administrations of isoxsuprine
Number of subjects: 0
Study 18705933 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (aspirin, dipyridamole or clopidogrel alone or in dual combination)
Number of subjects: 250
Study 18705933 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation therapy (heparin followed by warfarin aiming for an INR in the range 2-3)
Number of subjects: 250
Study 15141368 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and nicotine replacement therapy
Number of subjects: 237
Study 15141368 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 237
Study 11826694 — intervention group
Group type: EXPERIMENTAL
Intervention: Mygind position
Number of subjects: 5
Study 11826694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragan position
Number of subjects: 5
Study 11826694 — intervention group
Group type: COMPARATOR
Intervention: Mecca position
Number of subjects: 5
Study 11826694 — intervention group
Group type: COMPARATOR
Intervention: Head back position
Number of subjects: 5
Study 11736715 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily) and Ethambutol (15 mg/kg daily) for 3 months
Number of subjects: 31
Study 11736715 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 31
Study 9264222 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (Gamimune-N, Miles Pharmaceutical Co) 200 mg/kg monthly for 1 year
Number of subjects: 135
Study 9264222 — intervention group
Group type: COMPARATOR
Intervention: Control group (indeterminate patients with no evidence of infection)
Number of subjects: 135
Study 8518774 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (Uniphyllin Continus tablets) at a mean steady-state plasma level of 14 mg.l-1
Number of subjects: 22
Study 8518774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3501750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 100mg twice daily for 3 days
Number of subjects: 250
Study 3501750 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulphamethoxazole 160mg + 800mg twice daily for 3 days
Number of subjects: 250
Study 2403756 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy regimens containing Adriamycin (doxorubicin) and mitomycin-C
Number of subjects: 0
Study 2403756 — intervention group
Group type: COMPARATOR
Intervention: Supportive care only
Number of subjects: 0
Study 30718168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic hallux valgus splint
Number of subjects: 70
Study 30718168 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 70
Study 31503181 — intervention group
Group type: EXPERIMENTAL
Intervention: Good‐outcome group
Number of subjects: 18
Study 31503181 — intervention group
Group type: COMPARATOR
Intervention: Poor‐outcome group
Number of subjects: 18
Study 29248944 — intervention group
Group type: EXPERIMENTAL
Intervention: Amelogen Plus TW, Ultradent Products Inc.
Number of subjects: 40
Study 29248944 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Z350 XT, 3MESPE
Number of subjects: 40
Study 29248944 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study 25556355 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with zoledronic acid
Number of subjects: 38
Study 25556355 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy without zoledronic acid
Number of subjects: 38
Study 25556355 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 38
Study 23188217 — intervention group
Group type: EXPERIMENTAL
Intervention: Crural closure followed by fundoplication (group 1)
Number of subjects: 18
Study 23188217 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundoplication followed by crural closure (group 2)
Number of subjects: 18
Study 20882668 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intraoral electrostimulation device
Number of subjects: 114
Study 20882668 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 114
Study 19615303 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy for dyssynergic defecation
Number of subjects: 0
Study 19615303 — intervention group
Group type: EXPERIMENTAL
Intervention: Management including education, counseling, diet, laxatives, and behavioral therapies
Number of subjects: 0
Study 19615303 — intervention group
Group type: COMPARATOR
Intervention: Surgical approaches (e.g., stapled transanal rectal resection)
Number of subjects: 0
Study 17256140 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I diagnostic scans
Number of subjects: 292
Study 17256140 — intervention group
Group type: COMPARATOR
Intervention: Post-treatment 131I scans
Number of subjects: 292
Study 17256140 — intervention group
Group type: COMPARATOR
Intervention: Negative diagnostic 123I scans
Number of subjects: 292
Study 17256140 — intervention group
Group type: COMPARATOR
Intervention: Pre- and post-treatment scans
Number of subjects: 292
Study 15083754 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP; 1,000 micrograms)
Number of subjects: 13
Study 15083754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 12530554 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP-supplemented formula
Number of subjects: 23
Study 12530554 — intervention group
Group type: COMPARATOR
Intervention: Control (nonsupplemented formula)
Number of subjects: 23
Study 9667348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 175
Study 9667348 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 0.5 mg
Number of subjects: 175
Study 9667348 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 1 mg
Number of subjects: 175
Study 9667348 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 2 mg
Number of subjects: 175
Study 9667348 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 8 mg
Number of subjects: 175
Study 9667348 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 16 mg
Number of subjects: 175
Study 9667348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 9667348 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of ondansetron
Number of subjects: 175
Study 9667348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea scores
Number of subjects: 175
Study 9667348 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction via VAS
Number of subjects: 175
Study 7536263 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic removal of catheter 24 hours after transurethral incision (group 1 - 52 patients)
Number of subjects: 213
Study 7536263 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic removal of catheter 48 hours after transurethral resection (group 1 - 54 patients)
Number of subjects: 213
Study 7536263 — intervention group
Group type: COMPARATOR
Intervention: Control group with catheterization interval determined by surgeon (group 2 - 52 patients)
Number of subjects: 213
Study 7536263 — intervention group
Group type: COMPARATOR
Intervention: Control group with catheterization interval determined by surgeon (group 2 - 55 patients)
Number of subjects: 213
Study 2719233 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 122
Study 2719233 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 122
Study 197982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 10
Study 197982 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Number of subjects: 10
Study 31486399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose biomembrane
Number of subjects: 46
Study 31486399 — intervention group
Group type: COMPARATOR
Intervention: Collagenase dressing
Number of subjects: 46
Study 26051565 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (two capsules daily for seven days before menstruation and for three days after menstruation for three successive cycles)
Number of subjects: 70
Study 26051565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two capsules daily for seven days before menstruation and for three days after menstruation for three successive cycles)
Number of subjects: 70
Study 26051565 — intervention group
Group type: COMPARATOR
Intervention: Curcumin vs Placebo
Number of subjects: 70
Study 23182405 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 52419
Study 23182405 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 52419
Study 21054553 — intervention group
Group type: EXPERIMENTAL
Intervention: Mallet osteotomes (Group 1, n=98)
Number of subjects: 196
Study 21054553 — intervention group
Group type: COMPARATOR
Intervention: Screwable osteotomes (Group 2, n=98)
Number of subjects: 196
Study 18820592 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg estradiol (Vagifem)
Number of subjects: 20
Study 18820592 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g (0.625 mg) conjugated estrogens (Premarin cream)
Number of subjects: 20
Study 17990769 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated group (11 patients, 13 hips) treated by THA using the non-image based surgical navigation system
Number of subjects: 23
Study 17990769 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 patients, 13 hips) treated by traditional THA
Number of subjects: 23
Study 15587240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender scent
Number of subjects: 73
Study 15587240 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary scent
Number of subjects: 73
Study 15587240 — intervention group
Group type: COMPARATOR
Intervention: Control (water scent)
Number of subjects: 73
Study 11307048 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 3
Study 11307048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 9533262 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian estimation methods
Number of subjects: 0
Study 9533262 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Bayesian estimation methods
Number of subjects: 0
Study 9533262 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully-parametric methods
Number of subjects: 0
Study 9533262 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-parametric methods
Number of subjects: 0
Study 9533262 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric methods
Number of subjects: 0
Study 8033428 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/kg IVIG every 4 weeks
Number of subjects: 36
Study 8033428 — intervention group
Group type: COMPARATOR
Intervention: 250 mg/kg IVIG every 4 weeks
Number of subjects: 36
Study 2672385 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose piperacillin
Number of subjects: 0
Study 2672385 — intervention group
Group type: COMPARATOR
Intervention: Multidose cefoxitin
Number of subjects: 0
Study 30508206 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous style
Number of subjects: 251
Study 30508206 — intervention group
Group type: COMPARATOR
Intervention: Paternalistic style
Number of subjects: 251
Study 29332430 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine phosphate sodium (1.0 g/100 ml 0.9% saline)
Number of subjects: 120
Study 29332430 — intervention group
Group type: COMPARATOR
Intervention: 100 ml 0.9% saline (control)
Number of subjects: 120
Study 26818484 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted systems-based package to improve penicillin delivery, aligned with elements of the Chronic Care Model, with continuous quality improvement processes including 3-monthly feedback to clinic staff.
Number of subjects: 300
Study 26818484 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted systems-based package to improve penicillin delivery, aligned with elements of the Chronic Care Model.
Number of subjects: 300
Study 24325931 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal embolic protection devices (n = 161)
Number of subjects: 239
Study 24325931 — intervention group
Group type: COMPARATOR
Intervention: Nonuse of distal embolic protection devices (n = 78)
Number of subjects: 239
Study 24325931 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery stent placement
Number of subjects: 239
Study 22121130 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) plus methotrexate (MTX)
Number of subjects: 531
Study 22121130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 531
Study 20635776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 0
Study 20635776 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17618764 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean Intermittent Self-Catheterization (CISC)
Number of subjects: 210
Study 17618764 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic Catheterization (SPC)
Number of subjects: 210
Study 15115243 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (FiO2 of 1.0 for 20 min)
Number of subjects: 8
Study 11591493 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (transdermal administration)
Number of subjects: 20
Study 11591493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9715571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus grafts with implants
Number of subjects: 1007
Study 9715571 — intervention group
Group type: COMPARATOR
Intervention: Various grafting materials and implant surfaces
Number of subjects: 1007